Skye reports Q4 loss $14.4M, cash $25.7M; initiates higher-dose CBeyond study after 22.3% weight loss at 52 weeks

Skye Bioscience, Inc.

Net loss Q4 2025: $14.4M; full year $55.9M; cash & equivalents $25.7M as of Dec 31, 2025.
Interim 52-week data: nimacimab+semaglutide achieved 22.3% mean weight loss; no plateau observed.
Initiated CBeyond Expansion Study: higher doses (400 mg and 600 mg IV) vs placebo; topline Q4 2026.
Weight regain during 13-week off-treatment: combo cohort regained 17.8% vs 37.3% for semaglutide alone.
FDA Type C meeting completed; feedback informing Phase 2b design including potential add-on with incretin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.